Interaction of 5-HT and HPA axis in depression and treatment-resistant depression

Yoshihisa Kitamura, Hiroaki Araki, Yutaka Gomita

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Psychoendocrinology studies of depressed patients focus on the disregulation of the hypothalamic-pituitary-adrenal (HPA) axis. Abnormalities in the HPA axis have been noted in depressed patients. Numerous data have demonstrated the existence of reciprocal interactions between the central serotonin (5-HT) system and HPA axis. These interactions are of particular relevance when considering pathological conditions, such as depression, in which modifications of both the 5-HT system and HPA axis have been evidenced. In our laboratory, we examined the effects of adrenocorticotropic hormone (ACTH) on the immobilization of rats in the forced swim test and on the wet-dog shakes induced by the DOI, 5-HT2 receptor agonist with the administration of imipramine and lithium. The reduction of immobility, induced by the chronic administration of imipramine for 15 days, was blocked by treatment with ACTH for 14 days. And, chronic ACTH treatment for 14 days increased the wet-dog shake response. This effect of ACTH was not inhibited by a 14-day administration of imipramine. Accordingly, the chronic treatment of rats with ACTH may prove to be an effective model for antidepressant-treatment-resistant depression. We believe that behavioral pharmacological and molecular biological research into the interaction between the 5-HT and HPA axis will elucidate the pathogenesis of depression or antidepressant-treatment-resistant depression and the mechanism of antidepressants action.

Original languageEnglish
Pages (from-to)319-325
Number of pages7
JournalFolia Pharmacologica Japonica
Volume119
Issue number6
DOIs
Publication statusPublished - 2002

Fingerprint

Treatment-Resistant Depressive Disorder
Adrenocorticotropic Hormone
Serotonin
Depression
Imipramine
Pituitary-Adrenal System
Antidepressive Agents
Serotonin 5-HT2 Receptor Agonists
Dogs
Lithium
Immobilization
Therapeutics
Pharmacology
Research

Keywords

  • Animal model
  • Depression
  • Hypothalamic-pituitary-adrenal axis
  • Serotonin
  • Treatment-resistant depression

ASJC Scopus subject areas

  • Pharmacology

Cite this

Interaction of 5-HT and HPA axis in depression and treatment-resistant depression. / Kitamura, Yoshihisa; Araki, Hiroaki; Gomita, Yutaka.

In: Folia Pharmacologica Japonica, Vol. 119, No. 6, 2002, p. 319-325.

Research output: Contribution to journalArticle

@article{7778838a8ede4d1abfe9de3968a53574,
title = "Interaction of 5-HT and HPA axis in depression and treatment-resistant depression",
abstract = "Psychoendocrinology studies of depressed patients focus on the disregulation of the hypothalamic-pituitary-adrenal (HPA) axis. Abnormalities in the HPA axis have been noted in depressed patients. Numerous data have demonstrated the existence of reciprocal interactions between the central serotonin (5-HT) system and HPA axis. These interactions are of particular relevance when considering pathological conditions, such as depression, in which modifications of both the 5-HT system and HPA axis have been evidenced. In our laboratory, we examined the effects of adrenocorticotropic hormone (ACTH) on the immobilization of rats in the forced swim test and on the wet-dog shakes induced by the DOI, 5-HT2 receptor agonist with the administration of imipramine and lithium. The reduction of immobility, induced by the chronic administration of imipramine for 15 days, was blocked by treatment with ACTH for 14 days. And, chronic ACTH treatment for 14 days increased the wet-dog shake response. This effect of ACTH was not inhibited by a 14-day administration of imipramine. Accordingly, the chronic treatment of rats with ACTH may prove to be an effective model for antidepressant-treatment-resistant depression. We believe that behavioral pharmacological and molecular biological research into the interaction between the 5-HT and HPA axis will elucidate the pathogenesis of depression or antidepressant-treatment-resistant depression and the mechanism of antidepressants action.",
keywords = "Animal model, Depression, Hypothalamic-pituitary-adrenal axis, Serotonin, Treatment-resistant depression",
author = "Yoshihisa Kitamura and Hiroaki Araki and Yutaka Gomita",
year = "2002",
doi = "10.1254/fpj.119.319",
language = "English",
volume = "119",
pages = "319--325",
journal = "Folia Pharmacologica Japonica",
issn = "0015-5691",
publisher = "Japanese Pharmacological Society",
number = "6",

}

TY - JOUR

T1 - Interaction of 5-HT and HPA axis in depression and treatment-resistant depression

AU - Kitamura, Yoshihisa

AU - Araki, Hiroaki

AU - Gomita, Yutaka

PY - 2002

Y1 - 2002

N2 - Psychoendocrinology studies of depressed patients focus on the disregulation of the hypothalamic-pituitary-adrenal (HPA) axis. Abnormalities in the HPA axis have been noted in depressed patients. Numerous data have demonstrated the existence of reciprocal interactions between the central serotonin (5-HT) system and HPA axis. These interactions are of particular relevance when considering pathological conditions, such as depression, in which modifications of both the 5-HT system and HPA axis have been evidenced. In our laboratory, we examined the effects of adrenocorticotropic hormone (ACTH) on the immobilization of rats in the forced swim test and on the wet-dog shakes induced by the DOI, 5-HT2 receptor agonist with the administration of imipramine and lithium. The reduction of immobility, induced by the chronic administration of imipramine for 15 days, was blocked by treatment with ACTH for 14 days. And, chronic ACTH treatment for 14 days increased the wet-dog shake response. This effect of ACTH was not inhibited by a 14-day administration of imipramine. Accordingly, the chronic treatment of rats with ACTH may prove to be an effective model for antidepressant-treatment-resistant depression. We believe that behavioral pharmacological and molecular biological research into the interaction between the 5-HT and HPA axis will elucidate the pathogenesis of depression or antidepressant-treatment-resistant depression and the mechanism of antidepressants action.

AB - Psychoendocrinology studies of depressed patients focus on the disregulation of the hypothalamic-pituitary-adrenal (HPA) axis. Abnormalities in the HPA axis have been noted in depressed patients. Numerous data have demonstrated the existence of reciprocal interactions between the central serotonin (5-HT) system and HPA axis. These interactions are of particular relevance when considering pathological conditions, such as depression, in which modifications of both the 5-HT system and HPA axis have been evidenced. In our laboratory, we examined the effects of adrenocorticotropic hormone (ACTH) on the immobilization of rats in the forced swim test and on the wet-dog shakes induced by the DOI, 5-HT2 receptor agonist with the administration of imipramine and lithium. The reduction of immobility, induced by the chronic administration of imipramine for 15 days, was blocked by treatment with ACTH for 14 days. And, chronic ACTH treatment for 14 days increased the wet-dog shake response. This effect of ACTH was not inhibited by a 14-day administration of imipramine. Accordingly, the chronic treatment of rats with ACTH may prove to be an effective model for antidepressant-treatment-resistant depression. We believe that behavioral pharmacological and molecular biological research into the interaction between the 5-HT and HPA axis will elucidate the pathogenesis of depression or antidepressant-treatment-resistant depression and the mechanism of antidepressants action.

KW - Animal model

KW - Depression

KW - Hypothalamic-pituitary-adrenal axis

KW - Serotonin

KW - Treatment-resistant depression

UR - http://www.scopus.com/inward/record.url?scp=0036308289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036308289&partnerID=8YFLogxK

U2 - 10.1254/fpj.119.319

DO - 10.1254/fpj.119.319

M3 - Article

VL - 119

SP - 319

EP - 325

JO - Folia Pharmacologica Japonica

JF - Folia Pharmacologica Japonica

SN - 0015-5691

IS - 6

ER -